nodes	percent_of_prediction	percent_of_DWPC	metapath
Etomidate—SLC2A1—forebrain—attention deficit hyperactivity disorder	0.0274	0.0989	CbGeAlD
Etomidate—SLC2A1—cardiovascular system—attention deficit hyperactivity disorder	0.0232	0.0836	CbGeAlD
Etomidate—CYP11B2—cardiovascular system—attention deficit hyperactivity disorder	0.0198	0.0716	CbGeAlD
Etomidate—SLC2A1—midbrain—attention deficit hyperactivity disorder	0.0181	0.0653	CbGeAlD
Etomidate—SLC2A1—nervous system—attention deficit hyperactivity disorder	0.0149	0.0537	CbGeAlD
Etomidate—SLC2A1—central nervous system—attention deficit hyperactivity disorder	0.0143	0.0517	CbGeAlD
Etomidate—SLC2A1—cerebellum—attention deficit hyperactivity disorder	0.014	0.0505	CbGeAlD
Etomidate—SLC2A1—brain—attention deficit hyperactivity disorder	0.0114	0.041	CbGeAlD
Etomidate—GABRB2—forebrain—attention deficit hyperactivity disorder	0.0107	0.0386	CbGeAlD
Etomidate—GABRG2—forebrain—attention deficit hyperactivity disorder	0.0107	0.0386	CbGeAlD
Etomidate—GABRA1—forebrain—attention deficit hyperactivity disorder	0.00944	0.0341	CbGeAlD
Etomidate—Diethylpropion—SLC6A3—attention deficit hyperactivity disorder	0.00892	0.281	CrCbGaD
Etomidate—CYP19A1—forebrain—attention deficit hyperactivity disorder	0.00866	0.0313	CbGeAlD
Etomidate—SLC2A1—Regulation of insulin secretion—ADRA2A—attention deficit hyperactivity disorder	0.00828	0.012	CbGpPWpGaD
Etomidate—GABRG2—GABA receptor activation—GABRQ—attention deficit hyperactivity disorder	0.0079	0.0114	CbGpPWpGaD
Etomidate—SLC2A1—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00782	0.0113	CbGpPWpGaD
Etomidate—ADRA2B—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.00716	0.0104	CbGpPWpGaD
Etomidate—GABRB2—midbrain—attention deficit hyperactivity disorder	0.00706	0.0255	CbGeAlD
Etomidate—GABRG2—midbrain—attention deficit hyperactivity disorder	0.00706	0.0255	CbGeAlD
Etomidate—ADRA2B—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.00701	0.0101	CbGpPWpGaD
Etomidate—GABRA1—GABA receptor activation—GABRQ—attention deficit hyperactivity disorder	0.00691	0.01	CbGpPWpGaD
Etomidate—SLC2A1—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.00684	0.00989	CbGpPWpGaD
Etomidate—ADRA2B—Platelet Aggregation (Plug Formation)—ADRA2C—attention deficit hyperactivity disorder	0.00653	0.00945	CbGpPWpGaD
Etomidate—SLC2A1—Integration of energy metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00651	0.00942	CbGpPWpGaD
Etomidate—GABRA1—midbrain—attention deficit hyperactivity disorder	0.00623	0.0225	CbGeAlD
Etomidate—ADRA2B—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.00602	0.0087	CbGpPWpGaD
Etomidate—ADRA2B—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.00589	0.00853	CbGpPWpGaD
Etomidate—GABRG2—nervous system—attention deficit hyperactivity disorder	0.0058	0.0209	CbGeAlD
Etomidate—GABRB2—nervous system—attention deficit hyperactivity disorder	0.0058	0.0209	CbGeAlD
Etomidate—GABRG2—central nervous system—attention deficit hyperactivity disorder	0.00559	0.0202	CbGeAlD
Etomidate—GABRB2—central nervous system—attention deficit hyperactivity disorder	0.00559	0.0202	CbGeAlD
Etomidate—ADRA2B—G alpha (z) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.00558	0.00808	CbGpPWpGaD
Etomidate—GABRG2—cerebellum—attention deficit hyperactivity disorder	0.00546	0.0197	CbGeAlD
Etomidate—GABRB2—cerebellum—attention deficit hyperactivity disorder	0.00546	0.0197	CbGeAlD
Etomidate—SLC2A1—HIF-2-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00543	0.00786	CbGpPWpGaD
Etomidate—SLC2A1—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00521	0.00754	CbGpPWpGaD
Etomidate—GABRA1—nervous system—attention deficit hyperactivity disorder	0.00512	0.0185	CbGeAlD
Etomidate—GABRB2—Orphan transporters—GABRQ—attention deficit hyperactivity disorder	0.00504	0.00729	CbGpPWpGaD
Etomidate—GABRA1—central nervous system—attention deficit hyperactivity disorder	0.00493	0.0178	CbGeAlD
Etomidate—SLC2A1—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00484	0.00701	CbGpPWpGaD
Etomidate—GABRA1—cerebellum—attention deficit hyperactivity disorder	0.00482	0.0174	CbGeAlD
Etomidate—CYP19A1—nervous system—attention deficit hyperactivity disorder	0.0047	0.017	CbGeAlD
Etomidate—Pseudoephedrine—MAOA—attention deficit hyperactivity disorder	0.00465	0.146	CrCbGaD
Etomidate—SLC2A1—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00465	0.00672	CbGpPWpGaD
Etomidate—GABRG2—Orphan transporters—GABRQ—attention deficit hyperactivity disorder	0.00461	0.00667	CbGpPWpGaD
Etomidate—CYP19A1—central nervous system—attention deficit hyperactivity disorder	0.00453	0.0163	CbGeAlD
Etomidate—GABRG2—brain—attention deficit hyperactivity disorder	0.00443	0.016	CbGeAlD
Etomidate—GABRB2—brain—attention deficit hyperactivity disorder	0.00443	0.016	CbGeAlD
Etomidate—SLC2A1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00428	0.00619	CbGpPWpGaD
Etomidate—ADRA2B—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.00425	0.00615	CbGpPWpGaD
Etomidate—Pethidine—SLC6A3—attention deficit hyperactivity disorder	0.00415	0.131	CrCbGaD
Etomidate—ADRA2B—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.00409	0.00591	CbGpPWpGaD
Etomidate—SLC2A1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00408	0.0059	CbGpPWpGaD
Etomidate—GABRA1—Orphan transporters—GABRQ—attention deficit hyperactivity disorder	0.00403	0.00583	CbGpPWpGaD
Etomidate—Pseudoephedrine—SLC6A3—attention deficit hyperactivity disorder	0.00401	0.126	CrCbGaD
Etomidate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.00397	0.00575	CbGpPWpGaD
Etomidate—ADRA2B—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00395	0.00571	CbGpPWpGaD
Etomidate—Pseudoephedrine—ADRA2A—attention deficit hyperactivity disorder	0.00393	0.124	CrCbGaD
Etomidate—GABRA1—brain—attention deficit hyperactivity disorder	0.00392	0.0141	CbGeAlD
Etomidate—ADRA2B—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.00382	0.00553	CbGpPWpGaD
Etomidate—ADRA2B—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00376	0.00544	CbGpPWpGaD
Etomidate—CYP19A1—FSH signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00373	0.0054	CbGpPWpGaD
Etomidate—ADRA2B—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00371	0.00537	CbGpPWpGaD
Etomidate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.00363	0.00526	CbGpPWpGaD
Etomidate—CYP19A1—brain—attention deficit hyperactivity disorder	0.00359	0.013	CbGeAlD
Etomidate—ADRA2B—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00357	0.00517	CbGpPWpGaD
Etomidate—GABRB2—Ion channel transport—GABRQ—attention deficit hyperactivity disorder	0.00354	0.00512	CbGpPWpGaD
Etomidate—ADRA2B—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00346	0.005	CbGpPWpGaD
Etomidate—ADRA2B—Platelet Aggregation (Plug Formation)—ADRA2A—attention deficit hyperactivity disorder	0.00343	0.00496	CbGpPWpGaD
Etomidate—CYP11B2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00339	0.0049	CbGpPWpGaD
Etomidate—ADRA2B—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00332	0.0048	CbGpPWpGaD
Etomidate—GABRG2—Ion channel transport—GABRQ—attention deficit hyperactivity disorder	0.00323	0.00468	CbGpPWpGaD
Etomidate—ADRA2B—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00321	0.00465	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.0032	0.00463	CbGpPWpGaD
Etomidate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.00318	0.0046	CbGpPWpGaD
Etomidate—ADRA2B—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00316	0.00457	CbGpPWpGaD
Etomidate—ADRA2B—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00312	0.00452	CbGpPWpGaD
Etomidate—Pethidine—SLC6A4—attention deficit hyperactivity disorder	0.0031	0.0977	CrCbGaD
Etomidate—Pseudoephedrine—SLC6A4—attention deficit hyperactivity disorder	0.003	0.0943	CrCbGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00299	0.00432	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (z) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00293	0.00424	CbGpPWpGaD
Etomidate—SLC2A1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00293	0.00424	CbGpPWpGaD
Etomidate—CYP11B1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00292	0.00422	CbGpPWpGaD
Etomidate—ADRA2B—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00291	0.00421	CbGpPWpGaD
Etomidate—GABRA1—Ion channel transport—GABRQ—attention deficit hyperactivity disorder	0.00283	0.00409	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—EP300—attention deficit hyperactivity disorder	0.00277	0.00401	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00273	0.00395	CbGpPWpGaD
Etomidate—ADRA2B—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00242	0.0035	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00239	0.00346	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00229	0.00331	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.00222	0.00321	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00209	0.00303	CbGpPWpGaD
Etomidate—ADRA2B—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00204	0.00295	CbGpPWpGaD
Etomidate—SLC2A1—Disease—STUB1—attention deficit hyperactivity disorder	0.00197	0.00285	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00183	0.00265	CbGpPWpGaD
Etomidate—CYP11B2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00181	0.00262	CbGpPWpGaD
Etomidate—CYP11B2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.0018	0.0026	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00179	0.00259	CbGpPWpGaD
Etomidate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.00175	0.00253	CbGpPWpGaD
Etomidate—CYP19A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00165	0.00239	CbGpPWpGaD
Etomidate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.0016	0.00231	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00156	0.00226	CbGpPWpGaD
Etomidate—CYP11B1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00156	0.00226	CbGpPWpGaD
Etomidate—CYP11B1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00155	0.00224	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00154	0.00223	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00153	0.00221	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00149	0.00216	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.00149	0.00215	CbGpPWpGaD
Etomidate—SLC2A1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00149	0.00215	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00142	0.00205	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.0014	0.00202	CbGpPWpGaD
Etomidate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.0014	0.00202	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00138	0.002	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00135	0.00196	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00134	0.00194	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00131	0.0019	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00129	0.00187	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00128	0.00186	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00123	0.00178	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00122	0.00177	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00122	0.00177	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.0012	0.00174	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00119	0.00172	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00119	0.00172	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00118	0.00171	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00118	0.00171	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00117	0.0017	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00116	0.00168	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00113	0.00163	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00112	0.00162	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00109	0.00158	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00107	0.00155	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00105	0.00152	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00103	0.00149	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00101	0.00146	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00101	0.00146	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000997	0.00144	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000984	0.00142	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000978	0.00141	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000978	0.00141	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000977	0.00141	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000962	0.00139	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000938	0.00136	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000937	0.00136	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000937	0.00136	CbGpPWpGaD
Etomidate—SLC2A1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000933	0.00135	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000926	0.00134	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000921	0.00133	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00092	0.00133	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000901	0.0013	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000897	0.0013	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000894	0.00129	CbGpPWpGaD
Etomidate—CYP19A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000885	0.00128	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000883	0.00128	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000883	0.00128	CbGpPWpGaD
Etomidate—CYP19A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000879	0.00127	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000873	0.00126	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000871	0.00126	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000866	0.00125	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000857	0.00124	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000847	0.00123	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000841	0.00122	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000835	0.00121	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.000821	0.00119	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00082	0.00119	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000806	0.00117	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000805	0.00117	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000804	0.00116	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000795	0.00115	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000782	0.00113	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000782	0.00113	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000772	0.00112	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000764	0.0011	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000762	0.0011	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000759	0.0011	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000749	0.00108	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000744	0.00108	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000741	0.00107	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000741	0.00107	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000738	0.00107	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000735	0.00106	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000731	0.00106	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000725	0.00105	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000719	0.00104	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000717	0.00104	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00071	0.00103	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000705	0.00102	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000702	0.00102	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000689	0.000997	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000667	0.000966	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000667	0.000966	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000653	0.000945	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000649	0.000939	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000645	0.000933	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000639	0.000924	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000632	0.000915	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000622	0.000899	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000614	0.000888	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000612	0.000885	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000592	0.000857	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000588	0.000851	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000572	0.000827	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000567	0.000821	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000563	0.000815	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000535	0.000774	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000511	0.00074	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000511	0.00074	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000509	0.000737	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000503	0.000728	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000499	0.000722	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000497	0.000719	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000482	0.000697	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000473	0.000685	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000468	0.000677	CbGpPWpGaD
Etomidate—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000467	0.000676	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000467	0.000676	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000462	0.000669	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000453	0.000655	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000449	0.000649	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000441	0.000638	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000441	0.000638	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000435	0.00063	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000434	0.000627	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000423	0.000612	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000421	0.000609	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000411	0.000594	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000409	0.000592	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000407	0.000589	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000403	0.000583	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000401	0.00058	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000389	0.000563	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000387	0.000561	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000362	0.000524	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000359	0.000519	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000352	0.00051	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000346	0.0005	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000335	0.000485	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000318	0.00046	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000314	0.000454	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—COMT—attention deficit hyperactivity disorder	0.00031	0.000448	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000308	0.000445	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000305	0.000441	CbGpPWpGaD
Etomidate—SLC2A1—Disease—EP300—attention deficit hyperactivity disorder	0.000303	0.000439	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000302	0.000437	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000298	0.000432	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000281	0.000407	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000274	0.000397	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000273	0.000395	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000272	0.000394	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000268	0.000387	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000267	0.000387	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000267	0.000386	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000265	0.000384	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000264	0.000382	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000262	0.00038	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000257	0.000372	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000255	0.000369	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000254	0.000368	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00025	0.000361	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00025	0.000361	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000247	0.000358	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000246	0.000356	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000246	0.000356	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000243	0.000351	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00024	0.000347	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000228	0.000331	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000223	0.000323	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.0002	0.000289	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00019	0.000275	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000185	0.000268	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000172	0.000249	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000162	0.000235	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000157	0.000226	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000151	0.000219	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000151	0.000218	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00015	0.000217	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000146	0.000211	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000146	0.000211	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000144	0.000209	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000143	0.000208	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000142	0.000205	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—EP300—attention deficit hyperactivity disorder	0.000133	0.000192	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000132	0.000191	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000115	0.000166	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.25e-05	0.000134	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—EP300—attention deficit hyperactivity disorder	6.49e-05	9.39e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.9e-05	7.09e-05	CbGpPWpGaD
